Adrián LLerena MD PhD
Adrián LLerena MD PhD
Professor. University of Extremadura. CICAB Clinical Research Centre at Extremadura University
Dirección de correo verificada de unex.es - Página principal
TítuloCitado porAño
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
L Bertilsson, JA Carrillo, ML Dahl, A Llerena, C Alm, U Bondesson, ...
British journal of clinical pharmacology 38 (5), 471-473, 1994
3111994
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …
JK Hicks, JR Bishop, K Sangkuhl, DJ Müller, Y Ji, SG Leckband, ...
Clinical Pharmacology & Therapeutics 98 (2), 127-134, 2015
2992015
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Ü Yasar, C Forslund‐Bergengren, G Tybring, P Dorado, A LLerena, ...
Clinical Pharmacology & Therapeutics 71 (1), 89-98, 2002
2162002
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
A LLerena, C Alm, ML Dahl, B Ekqvist, L Bertilsson
Therapeutic drug monitoring 14 (2), 92-97, 1992
1771992
Relationship between personality and debrisoquine hydroxylation capacity: suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
A Llerena, G Edman, J Cobaleda, J Benitez, D Schalling, L Bertilsson
Acta Psychiatrica Scandinavica 87 (1), 23-28, 1993
1751993
Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
ML Dahl, A Llerena, U Bondesson, L Lindstrom, L Bertilsson
British journal of clinical pharmacology 37 (1), 71-74, 1994
1161994
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
A LLerena, ML Dahl, B Ekqvist, L Bertilsson
Therapeutic drug monitoring 14 (3), 261-264, 1992
1101992
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
A Llerena, J Cobaleda, C Martinez, J Benitez
European journal of drug metabolism and pharmacokinetics 21 (2), 129-138, 1996
1091996
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
P Dorado, R Berecz, MJ Norberto, Ü Yasar, ML Dahl, A LLerena
European journal of clinical pharmacology 59 (3), 221-225, 2003
1072003
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations
A LLerena, MEG Naranjo, F Rodrigues-Soares, EM Penas-LLedo, ...
Expert opinion on drug metabolism & toxicology 10 (11), 1569-1583, 2014
1032014
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education
D Gurwitz, JE Lunshof, G Dedoussis, CS Flordellis, U Fuhr, J Kirchheiner, ...
The pharmacogenomics journal 5 (4), 221, 2005
992005
Pharmacogenomic information in drug labels: European Medicines Agency perspective
F Ehmann, L Caneva, K Prasad, M Paulmichl, M Maliepaard, A Llerena, ...
The pharmacogenomics journal 15 (3), 201, 2015
852015
QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
A Llerena, R Berecz, P Dorado, A de la Rubia
Journal of psychopharmacology 18 (2), 189-193, 2004
812004
Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
JA Carrillo, SI Ramos, AG Herraiz, A Llerena, JAG Agundez, R Berecz, ...
Journal of clinical psychopharmacology 19 (6), 494-499, 1999
811999
Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
A LLerena, P Dorado, F O'kirwan, R Jepson, J Licinio, ML Wong
The pharmacogenomics journal 4 (6), 403, 2004
782004
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
A LLerena, P Dorado, EM Peñas-Lledó
Future Medicine Ltd 10 (1), 17-28, 2009
762009
Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
P Dorado, MC Cáceres, E Pozo-Guisado, ML Wong, J Licinio, A LLerena
Biotechniques 39 (10 Suppl), S571-S754, 2005
762005
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
A Llerena, P Dorado, R Ramírez, I González, M Alvarez, EM Peñas-Lledó, ...
The pharmacogenomics journal 12 (2), 176, 2012
752012
Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden
RA Kiivet, A Llerena, ML Dahl
Br J Clin Pharmacol 40, 467-76, 1995
751995
Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers
I González, EM Peñas-Lledó, B Pérez, P Dorado, M Álvarez, A LLerena
Future Medicine Ltd 9 (7), 833-840, 2008
742008
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20